Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Amniel Pharmaceuticals Second Quarter 2025 Earnings Call. I will now turn the call over to Amniel's Head of Investor Relations, Tony DiMeo. Good morning, and thank you for joining Amniel Pharmaceuticals Second Quarter 2025 Earnings Call. Today, we issued a press release reporting Q2 results. The earnings press release and presentation are available at amniel.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward-Looking Statements for factors that may impact future performance. We also discussed non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Sharad and Shintu Patel, co-founders and co-CEOs, Carlos Conidera, CFO, our commercial leaders, Andy Boyer for Affordable Medicines, Joe Renda for Specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Sharad. Thank you, Tony. Good morning, everyone. The second quarter was another consecutive quarter of strong performance and growth, with revenues of 720 million and adjusted EBITDA of $184 million. At the halfway point of the year, and with confidence in our outlook, we are pleased to raise 2025 guidance. I'm so excited to walk you through the multiple growth drivers that are shaping the future of MNIL. At MNIL, we focus each day on delivering innovative and affordable medicines that are essential for patients. Since our founding in 2002, we have methodically diversified beyond genetics to build a broad and di...